login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
IMMUNOME INC (IMNM) Stock News
USA
- NASDAQ:IMNM -
US45257U1088
-
Common Stock
16.74
USD
+0.49 (+3.02%)
Last: 10/21/2025, 7:24:26 PM
16.9
USD
+0.16 (+0.96%)
After Hours:
10/21/2025, 7:24:26 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
IMNM Latest News, Press Relases and Analysis
All
Press Releases
19 days ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
a month ago - By: Benzinga
Where Immunome Stands With Analysts
a month ago - By: Benzinga
- Mentions:
AGX
CROX
HUM
KOS
...
This Crocs Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday
a month ago - By: Infinimmune
Infinimmune Announces Research Collaboration with Immunome
2 months ago - By: Stocktwits
- Mentions:
IWMW
VTWG
Immunome Stock Rises After Craig-Hellum Initiates Coverage With $26 Price Target: Here’s Why The Analyst Sees An ‘Attractive Entry Point’
2 months ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2 months ago - By: Immunome, Inc.
Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference
3 months ago - By: Zacks Investment Research
- Mentions:
DTIL
Immunome, Inc. (IMNM) Reports Q2 Loss, Beats Revenue Estimates
3 months ago - By: The Motley Fool
Immunome (IMNM) Q2 Revenue Surges 382%
3 months ago - By: Zacks Investment Research
- Mentions:
VYGR
Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: Immunome, Inc.
Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update
3 months ago - By: Zacks Investment Research
- Mentions:
JAZZ
Jazz Pharmaceuticals (JAZZ) Reports Q2 Loss, Misses Revenue Estimates
3 months ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4 months ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5 months ago - By: Zacks Investment Research
Wall Street Analysts Think Immunome (IMNM) Could Surge 188.57%: Read This Before Placing a Bet
5 months ago - By: Immunome, Inc.
Immunome to Present at Upcoming Investor Conferences
5 months ago - By: Zacks Investment Research
- Mentions:
CDXS
Immunome, Inc. (IMNM) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: Zacks Investment Research
- Mentions:
BOLT
Bolt Biotherapeutics, Inc. (BOLT) Reports Q1 Loss, Tops Revenue Estimates
5 months ago - By: Yahoo Finance
- Mentions:
TEVA
JPM
ENTA
PSTV
...
Why Teva Pharmaceuticals Stock Blasted 6% Higher Today
5 months ago - By: Immunome, Inc.
Immunome Reports First Quarter 2025 Financial Results and Provides Business Update
6 months ago - By: Zacks Investment Research
Wall Street Analysts Believe Immunome (IMNM) Could Rally 249.93%: Here's is How to Trade
6 months ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 months ago - By: Immunome, Inc.
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference
7 months ago - By: Immunome, Inc.
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
7 months ago - By: Immunome, Inc.
Immunome Reports Full Year 2024 Financial Results and Provides Business Update
8 months ago - By: Immunome, Inc.
Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC
Please enable JavaScript to continue using this application.